# Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

> **NCT04477486** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 13 (actual)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04477486
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-23
- **Primary completion:** 2022-02-09
- **Final completion:** 2025-05-28
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04477486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04477486, "Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04477486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*